HMR3647A_4017. This study was performed in the United States of america.
An american prospective, randomized, double-blinded, active-controlled study for the evaluation of the efficacy, safety, and pharmacoeconomics of oral telithromycin (Ketek) 800 mg once a day for 5 days vs moxifloxacin (Avelox) 400 mg once a day for 10 days in the treatment of acute maxillary sinusitis (AMS) in adults.
The summary result information on clinical trials is provided by the sanofi-aventis Group for informational purposes only and is not intended to promote any product or use. Summaries of clinical study results are intended to report the results of the study that were known at the time of the study’s completion. The summaries therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available, and the sanofi-aventis Group makes no representation or warranty of any kind as to the currency or completeness of the information contained in any summary, and disclaims all warranties, express or implied, with respect to such information. Healthcare Professionals should refer to the current approved product labeling for information on approved indications in their country. This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional. |
